{
  "source": "PA-Notification-Orgovyx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1350-5\nProgram Prior Authorization/Notification\nMedication Orgovyx™ (relugolix)\nP&T Approval Date 2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nOrgovyx (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated\nfor the treatment of adult patients with advanced prostate cancer.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Orgovyx will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Prostate Cancer\n1. Initial Authorization\na. Orgovyx will be approved based on the following:\n(1) Diagnosis of advanced prostate cancer\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Orgovyx will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Orgovyx\ntherapy\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanage",
    "ed for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• Please refer to plan specifics to determine exclusion status.\n4. References:\n1. Orgovyx [package insert]. Marlborough, MA: Sumitomo Pharma America, Inc.; October\n2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed December 20,\n2024.\nProgram Prior Authorization/Notification – Orgovyx™ (relugolix)\nChange Control\n2/2021 New program.\n2/2022 Annual review with no changes to coverage criteria. Updated\nreferences.\n2/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n2/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n2/2025 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}